Celgene raised Revlimid price effective January 3

On the same day Celgene (CELG) announced its proposed takeover by Bristol-Myers (BMY), the company was also hiking the price of its blockbuster cancer drug, Bloomberg reports. Celgene raised the price of a 10-milligram dose of Revlimid by 3.5% to $719.82 effective January 3, the report says, citing price data compiled by Bloomberg Intelligence and First Databank. The biotechnology company also hiked the price of psoriasis therapy Otezla, the cancer treatment Abraxane, and two other drugs by the same percentage, the report notes. Celgene spokesman Greg Geissman said the 3.5% raise is lower than the expected rate of spending growth in U.S. health care, according to Bloomberg
https://thefly.com/landingPageNews.php?id=2843971